|
Abelacimab’s Stroke Uncertainty | Keros Quits TROPOS
January 27, 2025
|
|
|
|
|
Together with
|
|
|
|
“…until we have pivotal large clinical trials that can demonstrate that these drugs are effective, their future will be uncertain.”
|
|
u003cspan style=u0022font-weight: 400;u0022u003eJonathan Piccini, MD on the impact of u003c/spanu003eu003ca href=u0022https://www.tctmd.com/news/azalea-timi-71-abelacimab-slashes-bleeds-vs-rivaroxaban-af-stroke-impact-unclearu0022u003eu003cspan style=u0022font-weight: 400;u0022u003eAZALEA-TIMI 71u003c/spanu003eu003c/au003e
|
|
|
|
Anthos Therapeutics published the full results of its Phase 2 AZALEA-TIMI 71 trial for its novel Factor XI inhibitor, abelacimab, confirming the drug’s lower bleeding risks, but leaving researchers uncertain about its ability to prevent stroke in AFib patients.
- Current guidelines recommend direct-acting oral anticoagulants (DOACs) for AFib because they reduce ischemic stroke with a lower risk of brain hemorrhage.
- Unfortunately, DOACs often cause gastrointestinal bleeding, which prompted the development of new stroke-prevention methods like Factor XI inhibition.
- By inhibiting Factor XI (an anticoagulation enzyme), drugs like abelacimab potentially prevent thrombosis without increasing spontaneous bleeding risks.
To see if abelacimab was a safer alternative, researchers randomized 1,287 AFib patients at risk of stroke to receive abelacimab (either 150mg or 90mg) or rivaroxaban (20mg), and indeed found that abelacimab treatment substantially reduced bleeding during a 2.1 year follow-up.
- Abelacimab 150mg led to a 62% reduction in major or clinically relevant bleeding and an 89% reduction in gastrointestinal bleeding compared to rivaroxaban.
- This bleeding reduction was so overwhelming that IDMC stopped the whole trial after only 21 months.
- Monthly 150mg doses of abelacimab also led to 99% inhibition of Factor XI that was sustained over 2 years.
While abelacimab aced its primary outcome, and AZALEA-TIMI 71 wasn’t designed for evaluating clinical efficacy, its exploratory endpoints didn’t show stroke advantages versus DOACs.
- Both abelacimab 150mg and 90mg led to higher incidence rates of stroke than rivaroxaban (1.21 & 1.36 per 100 person-years vs. 0.83).
- Abelacimab’s ischemic stroke incidence rates were similar (1.21 & 1.24), far higher than rivaroxaban’s rate of 0.59 per 100 person-year.
However, lingering questions about abelacimab’s stroke impact should be clarified by the LILAC Phase 3 study, which launched in 2023 and is designed to further explore abelacimab’s clinical efficacy.
These early glimpses into abelacimab’s stroke prevention aren’t unique, with both Bayer and Bristol Myers-Squibb running into similar study issues for their Factor XI inhibitors.
- Bayer terminated its OCEANIC-AF trial for its Factor XI inhibitor, asundexian, due to 3X greater stroke (1.3% vs. 0.4%) and 4X ischemic stroke rates (csHR = 4.06).
- Results from BMS’ AXIOMATIC-SSP study found that its factor XI inhibitor, milvexian, failed to meaningfully reduce ischemic stroke.
The Takeaway
AZALEA-TIMI 71 provides incredibly strong evidence that Athos’ abelacimab reduces bleeding risks (the study’s primary endpoint), but we’ll need to see the results of the LILAC study before drawing conclusions on stroke prevention. Ultimately, without strong stroke results in future studies, abelacimab and other factor XI inhibitors may struggle to replace DOACs.
|
|
|
AI Analysis of ATTR-CM
ATTR-CM is a progressive and fatal cardiomyopathy with a rising number of diagnoses and a highly variable clinical course. See how Us2.ai’s fully automated machine learning algorithm analyzes echocardiographic DICOM images without human interaction to improve tracking ATTR-CM progression and treatment responses.
|
|
Cardiology AI: From Research to Clinical Practice
Explore how AI algorithms are reshaping cardiology with insights from Tempus’ recent webinar, featuring Dr. David Ouyang of UCLA and Cedars-Sinai, alongside Tempus’ Dr. John Pfeifer and Dr. Brandon Fornwalt. This expert panel dives into how AI can bridge diagnostic gaps, enhance patient outcomes, and streamline workflows for conditions like AFib and pulmonary hypertension. Read the full recap to glimpse the future of AI-driven cardiology.
|
|
An All-in-One Coronary Care Solution
See how HeartFlow ONE is transforming precision heart care as the first all-in-one CCTA pathway, combining FFRCT, stenosis, and plaque analysis in a single workflow.
|
|
- Keros Cuts TROPOS: Keros Therapeutics entirely stopped the TROPOS phase 2 trial of its PAH drug, cibotercept, one month after reports of pericardial effusion shut down the trial’s two higher dose treatment arms. Despite the termination, Keros still plans to present top-line data from all three treatment arms in the second quarter of 2025. News of the first halted treatments sent the company’s stock plummeting by two thirds last month, with the full stop bringing its value down another 15%.
- Cornell’s Biodegradable Graft: Cornell engineers hope to push the limits of vascular grafts with their new biodegradable metallo-elastomer graft that could help with grafting vessels smaller than five millimeters. The biodegradable graft expands and contracts like human vasculature while allowing new cells to grow as the body absorbs it, addressing the stiffness and permanence of traditional Teflon grafts. The first application of the graft will be for dialysis patients, working their way towards cardiovascular applications.
- The Dangers of Sleeping Hypertension: New results from a JAMA study suggest your laying blood pressure could impact your risk of CVD more than expected. Researchers studied ~11k middle-aged adults without known CVD for over 27 years and found that supine hypertension (high BP while laying down) without seated hypertension increased patients’ risk of incident coronary heart disease (+60%), HF (+83%), stroke (+86%), fatal CHD (+118%), and all-cause mortality (+43%). These results mean future studies might need to account for nocturnal hypertension when collecting data.
- Salubris’ RENEU-HF Safety Results: Salubris Biotherapeutics announced positive interim data from the RENEU-HF Phase 2 trial of its selective ErbB4 agonist, JK07, for treating HFrEF and HFpEF patients. The pre-specified interim analysis explored the safety of JK07 at a 0.045 mg/kg dose and found that it was safe in all 68 patients. Following the interim results, RENEU-HF’s 0.09 mg/kg dose group opened for enrollment.
- Large Weight Swings Risky: Rapid swings in body weight could have adverse effects on patient health, especially in patients struggling with obesity. As part of a Heart study, researchers analyzed data from ~8.3k obese patients with CVD in the UK Biobank and found that large weight gain (≥10kg) led to a higher risk of CV death (aHR: 3.05) and all-cause mortality (1.93) compared to stable weight (gain or loss of ≤5kg).
- BSCI’s Late-Breaking Combo: Boston Scientific announced study data supporting both its FARAPULSE PFA System and the WATCHMAN FLX LAAC Device. Results from BSCI’s ADVANTAGE AF study found that the FARAPULSE achieved a composite effectiveness rate of 63.5% for addressing AF, re-ablation, cardioversion, and/or amiodarone use, while keeping 85.3% of patients free from recurrent AF. Meanwhile, subanalysis of its OPTION trial found the WATCHMAN FLX achieved a 44% reduction in non-procedural bleeding outcomes compared to oral anticoagulants at 36 months.
- HeartFlow & Boone’s CVD Touchdown: HeartFlow and the Denver-based Boone Heart Institute launched the GAMEFILM Registry to help define cardiac risk in retired NFL players. The GAMEFILM Registry will enroll approximately 120 NFL alumni and leverage CCTA imaging insights from the HeartFlow ONE platform to collect observational data to better understand their CAD prevalence, risk factors, severity, and treatment protocols. Starting with retired NFL players is particularly apt considering that one in three retired professional football players die of CVD.
- Pulse’s PFA Pushes On: Pulse Biosciences announced late-breaking data from its Nanosecond PFA 360° Cardiac Catheter System’s first-in-human feasibility study. Researchers examined the initial 118 patients treated with the device and found that 100% of lesions were successfully treated with conduction block, PVI success rate at three months was 92.4%, and total PVI ablation time lasted 11.6 minutes on average. One patient experienced a severe adverse event (cardiac perforation) and two experienced adverse events (vertigo and creatinine elevation).
- FTC Settles PE Roll-Up Case: In a move that could have implications for cardiology private practice consolidation, the FTC settled litigation against private equity firm Welsh, Carson, Anderson & Stowe that charged the company with trying to roll up anesthesiology practices in Texas to create a monopoly and drive up prices. The FTC ordered Welsh Carson to freeze its investment in its roll-up vehicle, U.S. Anesthesia Partners, and submit to increased oversight in the future.
- CCTA For Brave Hearts: Handing another win to CCTA, a prespecified analysis of SCOT-HEART’s 10-year outcomes suggests the imaging modality could significantly reduce CHD death and MACE for patients with chest pain. Researchers randomized ~4k patients to receive either standard care or CCTA + standard care and found that the CCTA group faced lower CHD death rates (6.6% vs. 8.2%) and MACE rates (8.3% vs. 10.3%) while experiencing higher preventative therapy rates (55.9% vs. 49%).
- Exercising for CAD QoL: While it’s not possible to run away from coronary artery disease, exercising could help with the health-related quality of life (HR-QoL) issues patients face. Scientists examined various combinations across 42 trials of exercise types (HIIT, HIIT + resistance, moderate-intensity training, and stretching-toning-balance training) and exercise settings (in-person or at-home), finding that all exercise types greatly improved HR-QoL but only at in-person settings.
|
|
Experience the Future of Learning: Medtronic Academy 2.0 is Here!
Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!
|
|
Automate Your Echo Reporting
It’s a good feeling when your echo report is already 83% complete before you even sit down to work on it. See how Centricity Cardio Enterprise’s echo automation features make this “good feeling” an everyday occurrence in this quick GE HealthCare demo video.
|
|
- Transforming Ischemia Detection: CCTA AI is poised to transform ischemia detection, leading to far greater diagnostic efficiencies and far fewer unnecessary invasive procedures. See how ischemia’s AI transformation is unfolding in this Cardiac Wire Show interview with Cleerly’s chief medical officer James Earls, MD.
- A Better Way to Coordinate Post-Stroke Care: Think your EHR messaging system might be holding back your post-stroke care? See how UC San Diego Medical Center streamlined its neuro and EP teams’ post-stroke workflow with Viz Connect, and the impact it had on cardiac monitor placements in inpatient and outpatient settings.
- Precise Intervals With ECG Algorithms: Read about how Monebo can help you provide precise interval measurement between any two fiducial points on the ECG waveform when you embed the Kinetic Intervals ECG Algorithm into your device or software suite.
- PIA Medical Processes It All: Need an analysis like calcium scoring, strain or even FFR? PIA Medical began as a Core Lab and can handle creative cardiac research and clinical trials along with the full breadth of clinical analyses available today.
- CVIS and AI in Structural Heart Treatment: Harnessing the power of CVIS and AI to enhance your heart imaging is crucial in today’s fast-paced health care environment. See how Optum’s CVIS can support clinical workflows and meet the needs of EP and structural heart procedures.
- Discover Innovation in Intervention: Explore how the AGENT™ Drug-Coated Balloon from Boston Scientific is advancing U.S.-based treatment options for patients with coronary artery disease. Rx Only. (Sponsored by Boston Scientific)
- From CPACS to CVIS: Cardiovascular imaging has come a long way from CPACS. Explore the evolution of cardiology image and data management in this Merge by Merative executive brief, and see what makes CVIS such a significant advancement.
|
|
|
|
|
